Cited by 143Advanced Proteomics Techniques and ApplicationsMetabolomics and Mass Spectrometry StudiesAlzheimer's disease research and treatments

Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer’s disease

Open access
Dey, Kaushik Kumar, Wang, Hong, Niu, Mingming, Bai, Bing, Wang, Xusheng, Li, Yuxin, Cho, Ji-Hoon, Tan, Haiyan +6 more·2019·Clinical Proteomics

Abstract

BACKGROUND: Blood-based protein measurement is a routine practice for detecting biomarkers in human disease. Comprehensive profiling of blood/plasma/serum proteome is a challenge due to an extremely large dynamic range, as exemplified by a small subset of highly abundant proteins. Antibody-based depletion of these abundant proteins alleviates the problem but introduces experimental variations. We aimed to establish a method for direct profiling of undepleted human serum and apply the method toward biomarker discovery for Alzheimer's disease (AD), as AD is the most common form of dementia without available blood-based biomarkers in clinic. METHODS: = 5) sera were analyzed in this pilot study. In addition, we implemented a multiplexed targeted LC-MS3 method (TOMAHAQ) for the validation of selected target proteins. RESULTS: The TMT-LC/LC-MS/MS platform is capable of analyzing 4826 protein components (4368 genes), covering at least 6 orders of magnitude in dynamic range, representing one of the deepest serum proteome analysis. We defined intra- and inter- group variability in the AD and control groups. Statistical analysis revealed differentially expressed proteins in AD (26 decreased and 4 increased). Notably, these altered proteins are enriched in the known pathways of mitochondria, fatty acid beta oxidation, and AGE/RAGE. Finally, we set up a TOMAHAQ method to confirm the decrease of PCK2 and AK2 in our AD samples. CONCLUSIONS: Our results show an ultra-deep serum discovery study by TMT-LC/LC-MS/MS, and a validation experiment by TOMAHAQ targeted LC-MS3. The MS-based discovery and validation methods are of general use for biomarker discovery from complex biofluids (e.g. serum proteome). This pilot study also identified deregulated proteins, in particular proteins associated with mitochondrial function in the AD serum samples. These proteins may serve as novel AD candidate biomarkers.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12014-019-9237-1

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In this study, consistent and evident mitochondrial protein decreases were identified in Alzheimer's disease CSF and serum samples.

    “In this study, we identified consistent and evident mitochondrial protein decreases in AD CSF and serum samples, which have rarely reported until the availability of the deep CSF/serum profiling (our reference datasets) [25, 33].”

    From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [25]

    The Results and discussion section reports that 12 proteins downregulated in AD serum samples were localized in mitochondria. This paper profiles serum, not CSF, so it does not support the CSF part of the claim. No page number is available in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Mitochondrial protein decreases in Alzheimer's disease CSF and serum have rarely been reported until the availability of deep CSF/serum profiling.

    “In this study, we identified consistent and evident mitochondrial protein decreases in AD CSF and serum samples, which have rarely reported until the availability of the deep CSF/serum profiling (our reference datasets) [25, 33].”

    From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [25]

    The Results and discussion section (page unavailable) reports that deep serum profiling found 12 downregulated mitochondrial proteins in AD samples. The paper does not report mitochondrial protein decreases in CSF or establish that such decreases had rarely been reported before deep CSF/serum profiling. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • The authors' group previously used TMT-LC/LC-MS/MS to bypass depletion and detect about 5000 proteins in human CSF and serum.

    “More recently, our group utilized the superior separation capacity of the latest TMT-LC/LC-MS/MS to bypass the depletion step and detect about 5000 proteins in human CSF and serum toward AD biomarker discovery [18, 25].”
  • A large-scale proteomic profile of human serum specimens has revealed consistent mitochondrial protein changes between control and AD samples.

    “Recently, a large-scale proteomic profile of human serum specimens has revealed consistent mitochondrial protein changes between control and AD samples [152].”
  • Discovery TMT proteomics was recently applied to plasma samples of two independent cohorts to predict Aβ burden in preclinical disease with high accuracy.

    “For example, discovery TMT proteomics was recently applied to plasma samples of two independent cohorts to predict Aβ burden in preclinical disease with high accuracy [181].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Dey, K. K., Wang, H., Niu, M., Bai, B., Wang, X., Li, Y., Cho, J.-H., Tan, H., Mishra, A., High, A. A., Chen, P.-C., Wu, Z., Beach, T. G., & Peng, J.
Affiliations
  • St. Jude Children's Research Hospital (US)
  • Banner Sun Health Research Institute (US)
Corresponding author
Peng, Junmin
Venue
Clinical Proteomics
Published
2019-04-17
Volume
16
Issue
1
Pages
16-16
ISSN
  • 1542-6416 (ISSN-L)
  • 1559-0275
OpenAlex
W2946202802
Cited by
135
References
61
Citations by year
2026: 13 · 2025: 16 · 2024: 10 · 2023: 19 · 2022: 20 · 2021: 31 · 2020: 22 · 2019: 4
FWCI
8.46
Type
journal article
Language
en
Open access
Locations
  • Clinical Proteomics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Institutes of Health (R01AG047928, R01AG053987, U24NS072026, P30AG19610, P30CA021765)
Topics
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, serum proteome, blood-based biomarkers, antibody depletion, differentially expressed proteins, mitochondrial function, fatty acid beta-oxidation, AGE-RAGE signaling pathway, PCK2, AK2, biomarker discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review